Traffic Lights - Latest Updates

Last updated: 09/02/2021

Other updates on this site
Drug Name Classification Clinical Indication Comments
ACETAZOLAMIDE (NEW) Amber Simple Idiopathic Intracranial hypertension
BEMPEDOIC ACID (Nilemdo®) (NEW) Black

Not yet reviewed

BEMPEDOIC ACID / EZETIMIBE (Nustendi®) (NEW) Black Primary hypercholesterolaemia or mixed dyslipidaemia

Not yet reviewed

BIFONAZOLE (Canesten Bifonazole Once Daily®) (NEW) Black Athlete’s foot

Not yet reviewed

BUPRENORPHINE PROLONGED RELEASE INJECTION (Buvidal®) Red Substance misuse

Used by Turning Point . If a patient is admitted to hospital contact turning point for advice about alternatives:

0116 3732117 – Direct dial to prescribing team

0116 3732108 – Direct Dial to Clinical Admin

0330 303 6000 – Main Switchboard

CEFIDEROCOL SULFATE TOSYLATE (Fetcroja®) (NEW) Black Treatment of infections due to aerobic Gram-negative organisms

Not yet reviewed

CELECOXIB (NEW) Amber Simple For pain and inflammation for asthmatic patients with NSAID allergy

To be initiated in a specialist clinic with resuscitation facilities

COLISTIN (NEW) Red Nebulised for Cystic fibrosis
COLISTIN (Colomycin ® and Promixin®) (NEW) Amber Simple Bronchiectasis

Please see guide for more information. Must be prescribed by brand as the brands are not interchangeable.

COLISTIN (Colomycin® and Promixin ®) (UPDATED) Amber Full SCA Nebulised for cystic fibrosis

Historic patients only. Must be prescribed by brand as the brands are not interchangeable.

DULOXETINE (UPDATED) Green Fibromyalgia & Neuropathic Pain
DUPILUMAB (Dupixent®) (NEW) Red Type 2 inflammation in asthma inadequately controlled by high dose ICS

As part of FOC scheme

ECULIZUMAB (NEW) Red Prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies
GIVOSIRAN (Givlaari®) (NEW) Black Acute hepatic porphyria

Not yet reviewed

IMIPENEM/CILASTATIN/ RELEBACTAM (Recarbrio®) (NEW) Black Treatment of infections due to aerobic gram negative organisms

Not yet reviewed

INDACATEROL/GLYCOPYRRONIUM/ MOMETASONE (Enerzair Breezhaler) (NEW) Black Maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Not yet reviewed

LIDOCAINE HYDROCHLORIDE + PHENAZONE EAR DROPS (Otigo®) (NEW) Black Local symptomatic treatment and relief of pain in specified diseases of the middle ear without tympanic perforation.

Not yet reviewed

NALDEMEDINE TOSYLATE (Rizmoic®) (UPDATED) Green opioid-induced constipation

As per NICE TA651.

 

OPICAPONE capsules (Ongentys®) (UPDATED) Amber Simple Parkinson's disease
OZANIMOD (Zeposia®) (NEW) Black Adults with active disease as part of relapsing-remitting Multiple Sclerosis.

Not yet reviewed

RITUXIMAB (NEW) Red Prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies
SEMAGLUTIDE (Rybelsus®) (NEW) Black Treatment of adults with insufficiently controlled type 2 diabetes

Not yet reviewed

SODIUM CROMOGLICATE CAPSULES (Nalcrom®) (UPDATED) Amber Simple Mast cell stabalisation including Haematology and food allergy indications
TIZANIDINE (UPDATED) Amber Simple Generalised spasticity for patients who have been stabilised on a dose

To revert to secondary care only, when there are any dose changes and doses of 12mg a day or more require secondary care prescribing for 4 months whilst monthly LFTs are undertaken by secondary care.

TOPIRAMATE (NEW) Amber Simple Idiopathic Intracranial hypertension
VOLANESORSEN (Waylivra®) (NEW) Red Familial chylomicronaemia syndrome in adults

In line with NICE HST13

VONICOG ALFA (Veyvondi®) (UPDATED) Red Von Willebrand disease

Other Updates on this Website

Recent documents from LMSG and TAS


About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more